UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 87

Sortiert nach

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

The New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350

2018

Volltextzugriff (PDF)

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929

2017

Volltextzugriff (PDF)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Journal of thoracic oncology, 2014-09, Vol.9 (9), p.1345-1353

2014

Volltextzugriff (PDF)

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma

Journal of thoracic oncology, 2015-05, Vol.10 (5), p.738-746

2015

Volltextzugriff (PDF)

New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background

Pathology oncology research, 2014-01, Vol.20 (1), p.11-25

2014

Volltextzugriff (PDF)

Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis

Journal of thoracic oncology, 2010-08, Vol.5 (8), p.1120-1129

2010

Volltextzugriff (PDF)

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)

PloS one, 2016-01, Vol.11 (1), p.e0144797-e0144797

2016

Volltextzugriff (PDF)

Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary

Frontiers in oncology, 2019-10, Vol.9, p.1051-1051

2019

Volltextzugriff (PDF)

Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non–Small Cell Lung Cancer

Clinical cancer research, 2005-10, Vol.11 (20), p.7344-7353

2005

Volltextzugriff (PDF)

Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer

Cancer research (Chicago, Ill.), 2006-07, Vol.66 (14), p.7341-7347

2006

Volltextzugriff (PDF)

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

BMC cancer, 2018-05, Vol.18 (1), p.598-598, Article 598

2018

Volltextzugriff (PDF)

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

Cancers, 2019-10, Vol.11 (10), p.1514

2019

Volltextzugriff (PDF)

Chromosomal Aberrations in Blood Lymphocytes as Predictors of Respiratory Function After Stereotactic Lung Irradiation

Frontiers in oncology, 2022-01, Vol.11, p.829972-829972

2022

Volltextzugriff (PDF)

Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease

Cytometry. Part A, 2008-03, Vol.73A (3), p.186-193

2008

Volltextzugriff (PDF)

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S261-S262

2017

Volltextzugriff (PDF)

High VEGFR-3–positive Circulating Lymphatic/Vascular Endothelial Progenitor Cell Level Is Associated with Poor Prognosis in Human Small Cell Lung Cancer

Clinical cancer research, 2009-03, Vol.15 (5), p.1741-1746

2009

Volltextzugriff (PDF)

Tüdőrák harminc év távlatából. Gondolatok a küzdelmes múltról, a jelen eredményeiről és az ígéretes jövőről

Lege artis medicinae, 2020, Vol.30 (11), p.515-519

Ostoros, Gyula

2020

Volltextzugriff (PDF)

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-06, Vol.376 (25), p.2415-2426

2017

Volltextzugriff (PDF)

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Volltextzugriff (PDF)

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

CA: a cancer journal for clinicians, 2023-11, Vol.73 (6), p.620-652

2023

Volltextzugriff (PDF)

Erythropoietin in cancer: an update

Current molecular medicine, 2008-09, Vol.8 (6), p.481

2008

Volltextzugriff (PDF)

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

The New England journal of medicine, 2023-11, Vol.389 (18), p.1672-1684

2023

Volltextzugriff (PDF)

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Clinical cancer research, 2019-04, Vol.25 (7), p.2088-2095

2019

Volltextzugriff (PDF)

Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer

Current opinion in oncology, 2023-01, Vol.35 (1), p.54

2023

Volltextzugriff (PDF)

1 – 25 von 87

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(86)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(52)
Science & Technology
(50)
Life Sciences & Biomedicine
(48)
Oncology
(43)
Female
(27)
Male
(26)
Lung Cancer
(23)
Middle Aged
(23)
Lung Neoplasms - Drug Therapy
(22)
Aged
(21)
Adult
(20)
Lung Neoplasms - Pathology
(20)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(14)
Mutation
(14)
Aged, 80 And Over
(13)
Antineoplastic Agents - Therapeutic Use
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Tumors
(12)
Chemotherapy
(11)
Respiratory System
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma

New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background

Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)

Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary

Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non–Small Cell Lung Cancer

Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

Chromosomal Aberrations in Blood Lymphocytes as Predictors of Respiratory Function After Stereotactic Lung Irradiation

Circulating bone marrow-derived endothelial progenitor cells: Characterization, mobilization, and therapeutic considerations in malignant disease

OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

High VEGFR-3–positive Circulating Lymphatic/Vascular Endothelial Progenitor Cell Level Is Associated with Poor Prognosis in Human Small Cell Lung Cancer

Tüdőrák harminc év távlatából. Gondolatok a küzdelmes múltról, a jelen eredményeiről és az ígéretes jövőről

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

Erythropoietin in cancer: an update

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study

Thoracic irradiation as consolidation therapy in patients with extensive-stage small cell lung cancer

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Suchergebnisse filtern